Disclosure: This is an affiliate site. We may earn compensation from partners. Full disclosure | Medical disclaimer
Two approvals landed in 2026. The bigger shift — drugs matching bariatric surgery results — is still a couple of years out.
2026 has already delivered two meaningful approvals: Foundayo (orforglipron), the first GLP-1 pill for weight loss that can be taken any time of day, approved April 1; and Wegovy HD, the 7.2 mg semaglutide dose approved March 19 with 20.7% mean weight loss.
What is coming next is a different order of magnitude. Retatrutide, Eli Lilly's triple agonist, produced 28.3% average weight loss at 80 weeks and 30.3% at 104 weeks in the phase 3 TRIUMPH-1 trial — figures that approach what bariatric surgery achieves.
This guide separates what you can actually get today from what is filed, what is in trial, and what is still years away. None of the drugs in the pipeline section are FDA-approved, and no telehealth provider can legitimately sell them to you now.
Retatrutide, CagriSema, survodutide and the other pipeline drugs on this page are not FDA-approved. Any product marketed to consumers under these names is not an approved medication. The FDA has warned about fraudulent compounded GLP-1 products carrying false label information and has issued warning letters to telehealth companies over compounded GLP-1 marketing claims. "Research peptides" sold for human use fall outside the regulated supply chain entirely.
These you can actually get with a prescription today.
| Medication | Molecule | Form | Average weight loss | Approved |
|---|---|---|---|---|
| Zepbound | Tirzepatide | Injection | 20.2% (SURMOUNT-5) | Available |
| Wegovy HD | Semaglutide 7.2 mg | Injection | 20.7% mean | March 19, 2026 |
| Wegovy | Semaglutide 2.4 mg | Injection and tablets | 13.7% (SURMOUNT-5) | Available |
| Foundayo | Orforglipron | Oral tablet | 11.1% at 17.2 mg | April 1, 2026 |
| Saxenda | Liraglutide | Daily injection | Lower than the above | Available |
Trial results and expected timelines. Regulatory dates slip routinely, so treat all of these as estimates rather than promises.
| Candidate | Mechanism | Reported weight loss | Status |
|---|---|---|---|
| Retatrutide (Lilly) | Triple agonist: GLP-1, GIP and glucagon | 28.3% at 80 weeks; 30.3% at 104 weeks (TRIUMPH-1) | Phase 3 complete; US filing planned early 2027 |
| CagriSema (Novo Nordisk) | Cagrilintide plus semaglutide | 22.7% over 68 weeks (REDEFINE-1) | Regulatory submission expected around early 2026 |
| MariTide (Amgen) | GIP receptor antagonist plus GLP-1 agonist | Over 24% in phase 2 | Phase 3 |
| Survodutide (Boehringer) | Dual GLP-1 and glucagon agonist | 16.6% at the highest dose | Phase 3 |
| Aleniglipron (GSBR-1290) | Oral GLP-1 | 11.3% over 38 weeks, no plateau observed | In development |
| Bimagrumab | Muscle-preserving agent, not a GLP-1 | Studied alongside GLP-1s | In development |
Cross-trial comparison is unreliable — different populations, durations and endpoints. Only SURMOUNT-5 was a direct head-to-head between two of these products.
Retatrutide is a triple agonist, acting on the GLP-1 receptor, the GIP receptor and the glucagon receptor. Semaglutide hits one of those; tirzepatide hits two. Adding glucagon-receptor activity appears to increase energy expenditure alongside the appetite effects, which is the leading explanation for the results.
In the pivotal phase 3 TRIUMPH-1 trial, participants on 12 mg retatrutide lost an average of 70.3 lbs — 28.3% of body weight — over 80 weeks, with 45.3% of participants achieving a reduction of 30% or more. At 104 weeks the average reached 30.3%. AJMC characterised these as matching bariatric surgery levels.
TRIUMPH-2, in adults with obesity and type 2 diabetes, reported up to 20.8% average weight loss at 80 weeks. Weight loss is typically lower in diabetic populations across this entire drug class, so that is consistent rather than disappointing.
On timing, reporting points to a US filing planned for early 2027, with some sources suggesting late 2026. Even on the optimistic end, FDA review takes many months, so a realistic US availability window is 2027 into 2028.
CagriSema pairs cagrilintide, an amylin analogue, with semaglutide. Because it builds on an already-approved molecule, its regulatory path is shorter, and submission was expected around early 2026 with a potential US launch late in the year.
REDEFINE-1 reported 22.7% average body weight loss over 68 weeks. That is a strong number in absolute terms and clearly ahead of Wegovy 2.4 mg at 13.7%.
It also landed below expectations. Novo had guided toward roughly 25%, and the shortfall moved the company's share price. This is a useful reminder that pipeline expectations and pipeline results routinely diverge, and that early phase 2 figures are a poor predictor of phase 3.
For patients, the practical question is whether 22.7% beats what you can get today. Against Wegovy HD at 20.7% and Zepbound at 20.2%, the margin is real but not transformative.
The most common mistake is waiting for something better instead of starting something that works.
The headline numbers belong to the injectables, but the more practical shift may be oral GLP-1s. Foundayo can be taken any time of day with no food or water restrictions, and aleniglipron showed 11.3% weight reduction over 38 weeks without a plateau. For people who will not inject, a pill at 11% they actually take beats an injection at 20% they abandon.
It is not approved yet. Reporting points to a planned US FDA filing in early 2027, with some sources suggesting late 2026, and FDA review takes many months after submission. A realistic US availability window is 2027 into 2028. Anyone offering to sell you retatrutide today is not selling an approved medication.
On trial results, considerably. Retatrutide produced 28.3% average weight loss at 80 weeks and 30.3% at 104 weeks in TRIUMPH-1, against 20.2% for tirzepatide and 13.7% for semaglutide 2.4 mg in the SURMOUNT-5 head-to-head. But it is not approved, has no real-world safety record, and cross-trial comparison is imperfect.
CagriSema pairs cagrilintide, an amylin analogue, with semaglutide. REDEFINE-1 reported 22.7% average weight loss over 68 weeks — strong, but below the roughly 25% Novo had guided toward. Regulatory submission was expected around early 2026, putting a potential US launch in late 2026.
Generally no. Nothing in the pipeline is available today, the nearest realistic launch is late 2026 at the earliest, and retatrutide is likely 2027 to 2028. Meanwhile Zepbound at 20.2% and Wegovy HD at 20.7% are already close to CagriSema's 22.7%. You can always switch to a newer drug later.
Not legitimately. Neither is FDA-approved, so no licensed provider can prescribe them for weight loss. Products sold under these names as "research peptides" sit outside the regulated supply chain, and the FDA has warned about fraudulent compounded GLP-1 products with false label information.
Two. Foundayo (orforglipron), the first GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, approved April 1, 2026. And Wegovy HD, the 7.2 mg semaglutide dose delivering 20.7% mean weight loss, approved March 19, 2026.
MariTide is Amgen's candidate, combining a GIP receptor antagonist with a GLP-1 agonist — a different approach from tirzepatide, which agonises both receptors. Phase 2 results showed weight loss exceeding 24%. It is in phase 3 and not approved.
Not on average. Foundayo produced 11.1% weight loss at its highest dose against roughly 20% for the leading injectables, and aleniglipron showed 11.3% over 38 weeks. The trade-off is adherence: for people who will not use injections, a pill they take consistently may outperform an injection they abandon.
The 7.2 mg dose approved March 2026
The GLP-1 pill approved April 2026
What you can get today, compared
Where to get an approved GLP-1 now
What each route costs
Why unapproved products are risky
Claims on this page trace to the following sources, checked on August 30, 2026.
Explore more expert guides and reviews to help you on your weight loss journey
Complete guide explaining the difference between semaglutide, Ozempic, Wegovy, and compounded semaglutide.
Complete guide to Jardiance weight loss: how much to expect, mechanism, and comparison to GLP-1 medications.
The SURMOUNT-5 head-to-head trial: 20.2% vs 13.7% average weight loss, plus side effects and cost.
What actually differs, what the FDA changed in 2026, and how the price gap closed.
The oral GLP-1 pill approved April 1, 2026: dosing from 0.8 mg, pricing from $149/mo, and results.
The higher-dose semaglutide approved March 19, 2026, delivering 20.7% mean weight loss.
This article summarizes publicly reported clinical trial results and regulatory timelines and is for informational purposes only. It is not medical advice, a diagnosis, or a treatment recommendation. Medications described as in development are NOT FDA-approved, are not available by prescription for weight loss, and their safety and effectiveness have not been established for general use. Regulatory timelines are estimates and frequently change. Never obtain or use an unapproved medication outside a regulated clinical trial. This page contains affiliate links, and we may earn compensation if you use them.
Date reviewed: August 30, 2026